115
Views
9
CrossRef citations to date
0
Altmetric
Original

Anticonvulsants Containing the N-(3-Aryl-2-propenoyl) amido Pharmacophore

, , , , , , , & show all
Pages 303-312 | Received 10 Dec 2003, Published online: 31 Jan 2011
 

Abstract

A series of 1-(3-aryl-2-propenoyl)-4-oxopiperidines (1) as well as some related semicarbazones (2) and thiosemi-carbazones (3) were prepared in order to determine whether the relative locations of aryl rings and amidic groups would lead to novel anticonvulsant agents. Initially the compounds were administered intraperito-neally to mice and examined in the maximal electroshock (MES), subcutaneous pentylenetetrazole (scPTZ) and neurotoxicity (NT) screens. The biodata revealed that anticonvulsant properties were displayed by most of the compounds in series (1), in half of the semicarbazones (2) while protection was absent by members of series (3). Molecular modeling was utilized in order to compare the positions of a phenyl ring in relation to amidic groups in representative compounds in series (1–3) with previously reported anticonvulsant agents. Molecular simplification of 4-oxo-1-(3-phenyl-2-propenoyl)piperidine (1a) led to 1-(3-phenyl-2-propenoyl)piperidine (7) and N,N-diethyl-cinnamamide (8) with retention of anticonvulsant properties. Both (1a) and (8) afforded protection in the hippocampal kindling screen in rats. When administered orally to rats, (1a) and (8) demonstrated activity in the MES screen and in the case of (8), a huge protection index was observed revealing it to be an important lead compound. The IC50 values of all of the compounds towards murine P388 cells were in excess of 50μM while several compounds displayed cytotoxicity towards Mycobacterium tuberculosis.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.